Log In
Print
BCIQ
Print
Print this Print this
 

VeriStrat

  Manage Alerts
Collapse Summary General Information
Company Biodesix Inc.
DescriptionBlood-based proteomic test for identifying patients likely to benefit from EGFR inhibitors
Molecular Target Epidermal growth factor receptor (EGFR)
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsPredict benefit of EGFR inhibitors in patients with non-small cell lung cancer (NSCLC); Predict benefit of EGFR inhibitors in patients with renal cell carcinoma (RCC); Predict benefit of EGFR inhibitors in patients with squamous cell carcinoma of the head and neck (SCCHN)
Regulatory Designation

Partner

Aveo Pharmaceuticals Inc.


 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today